Effect of anticoagulant drugs in cancer

Current Opinion in Pulmonary Medicine

Volumn 11, Issue 5, 2005, Pages 403-407

  Falanga, Anna ^a   Piccioli, Andrea ^b  

^a OSPEDALI RIUNITI   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Anticoagulants; Cancer; Low molecular weight heparin; Survival; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO;

ANTINEOPLASTIC ACTIVITY; BLOOD CLOTTING; CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CANCER TISSUE; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; HUMAN; MALIGNANT TRANSFORMATION; MELANOMA; PROGNOSIS; REVIEW; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 24744455445     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/01.mcp.0000174247.23009.06     Document Type: Review

References (28)

1. Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res 2001; 102:V215-V224.
2. Falanga A, Marchetti M, Vignoli A, Balducci D. Clotting mechanisms and cancer: implications in thrombus formation and tumor progression. Clin Adv Hematol Oncol 2003; 1:673-678.
3. Yu JL, May L, Lhotak V, et al. Oncogenic events regulate tissue factor expression in colorectal cancer: implications for tumor progression and angiogenesis. Blood 2005; 105:1734-1741. This very important study clearly demonstrates a causal relation between tissue malignant transformation, cancer coagulopathy, and neoangiogenesis. It suggests innovative models of targeting oncogene therapy.
4. Palumbo JS, Talmage KE, Massari JV, et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005; 105:178-185. This outstanding study elegantly shows in vivo, in a mouse model, an important link between hemostatic factors, innate immunity, and cancer. It provides a new tool for pharmacologic approaches.
5. Boccaccio C, Sabatino C, Medico E, et al. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 2005; 434:396-400. This important and very elegant study shows, in a mouse model, that an oncogene-determined malignant transformation also drives a program upregulating prothrombotic factors. A unique model of tumor-associated disseminated coagulopathy is presented.
6. Zacharski LR, Ornstein DL. Heparin and cancer. Thromb Haemost 1998; 80:10-23.
7. Colucci M, Delaini F, de Bellis Vitti G, et al. Warfarin inhibits both procoagulant activity and metastatic capacity of Lewis lung carcinoma cells: role of vitamin K deficiency. Biochem Pharmacol 1983; 32:1689-1691.
8. Mousa SA, Mohamed S. Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. Thromb Haemost 2004; 92:627-633.
9. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 2005; 6:401-410.
10. Falanga A. The effect of anticoagulant drugs on cancer. J Thromb Haemost 2004; 2:1263-1265.
11. Michaels L. Cancer incidence and mortality in patients having anticoagulant therapy. Lancet 1964; 22:832-835.
12. Zacharski LR, Henderson WG, Rickles FR, et al. Effect of warfarin on survival in small cell carcinoma of the lung. JAMA 1981; 245:831-835.
13. Maurer LH, Herndon JE 2nd, Hollis DR, et al. Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. J Clin Oncol 1997; 15:3378-3387.
14. Smorenburg SM, Vink R, Otten HM, et al. The effects of vitamin K-antagonists on survival of patients with malignancy: a systematic analysis. Thromb Haemost 2001; 86:1586-1587.
15. Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism: Duration of Anticoagulation Trial. N Engl J Med 2000; 342:1953-1958.
16. Kakkar AK, Hedges AR, Williamson RCN, et al. Perioperative heparin therapy inhibits late deaths from metastatic cancer. Int J Oncol 1995; 6:885-888.
17. Lebeau B, Chastang C, Brechot JM, et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. Cancer 1994; 74:38-44.
18. Smorenburg SM, Hettiarachchi RJ, Vink R, et al. The effects of unfractionated heparin on survival in patients with malignancy: a systematic review. Thromb Haemost 1999; 82:1600-1604.
19. Hettiarachchi RJ, Smorenburg SM, Ginsberg J, et al. Do heparins do more than just treat thrombosis? The influence of heparin on cancer spread. Thromb Haemost 1999; 82:947-952.
20. Wojtukiewicz M, Kozlowski L, Ostrowska K, et al. Low-molecular-weight heparin treatment for malignant melanoma: a pilot clinical trial. Thromb Haemost 2003; 89:405-406.
21. Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22:1944-1948. This study represents the first published large prospective controlled randomized trial to evaluate the effect on survival of long-term prophylactic-dose LMWH in patients with advanced solid malignancies without thrombosis.
22. Altinbas M, Coskun HS, Er O, et al. A randomized clinical trial of combination chemotherapy with and without low molecular weight heparin in small cell lung cancer. J Thromb Haemost 2004; 2:1266-1271. In this interesting prospective randomized study, the effect on survival of prophylactic-dose LMWH, in combination with chemotherapy, was tested in one specific type of cancer: small-cell lung cancer.
23. Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 23:2130-2135. This is the first large prospective randomized clinical study testing the effect of a higher dose (therapeutic + subtherapeutic) of LMWH on survival in patients with advanced malignancy without thrombosis.
24. Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin coumarin derivates on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23:2123-2129. This post-hoc analysis of the CLOT study gives important information on long-term therapeutic dose LMWH dalteparin compared with oral anticoagulation (International Normalized Ratio 2-3) in improving survival of cancer patients.
25. Klerk CPW, Smorenburg SM, Buller HR. Antimalignant properties of antithrombotic agents. In: Lugassy G, Falanga A, Kakkar AK, Rickles FR, editors. Thrombosis and cancer. London and New York, Martin Dunitz, Taylor & Francis Group, 2004; 59:207-222.
26. Borsig L, Wong R, Feramisco J, et al. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA 2001; 98:3352-3357.
27. Parish CR, Freeman C, Brown KJ, et al. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res 1999; 59:3433-3441.
28. Jayson GC, Gallagher JT. Heparin oligosaccharides: inhibitors of the biological activity of bFGF on Caco-2 cells. Br J Cancer 1997; 75:9-16.